Seleno-L-methionine modulation of nucleotide excision DNA repair relevant to cancer prevention and chemotherapy

Molecular and Cellular Pharmacology

Volumn 1, Issue 4, 2009, Pages 218-221

  Smith, Martin L ^a   Kumar, M A Suresh ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Cisplatin; DNA repair; Selenium

Indexed keywords

CARBOPLATIN; CELL DNA; CISPLATIN; PROTEIN P53; SELENOMETHIONINE; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER PREVENTION; DNA DAMAGE; EXCISION REPAIR; HUMAN; NONHUMAN;

EID: 77953372275     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.09.26     Document Type: Article

References (25)

1. Letavayová L, Vlasáková D, Vlcková V, Brozmanová J, and Chovanec M. Rad52 has a role in the repair of sodium selenite-induced DNA damage in Saccharomyces cerevisiae. Mutat Res. 2008;652:198-203
2. Hu H, Jiang C, Ip C, Rustum YM, and Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005;11:2379-88.
3. Meuillet E, Stratton S, Prasad-Cherukuri D. et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J. Cell Biochem 2004;91:443-58.
4. Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-63.
5. Reid MC, Stratton MS, Lillico AJ, et al. A report of high-dose selenium supplementation: response and toxicities. J. Trace Elem Biol 2004; 18:69-74.
6. Reid MC, Duffield-Lillico AJ, Slate E, et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer 2008; 60:155-63.
7. Fakih M, Cao S, Durrani FA, and Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach to the treatment of solid tumors. Clin Colorectal Cancer 2005;5:132-35.
8. Fakih MG, Pendyala L, Smith PF et al. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.Clin Cancer Res 2006 15;12:1237-44
9. Fakih MG, Pendyala L, Brady W et al. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol 2008;62:499-508
10. Cao S, Durrani FA, and Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10:2561-9.
11. Fischer JL, Mihelc E, Pollok KE, and Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 2007;6:355-61.
12. Fischer JL, Kumar MA, Day TW et al. The Xpc gene markedly affects cell survival in mouse bone marrow. Mutagenesis 2009;24:309-16.
13. Adimoolam S and Ford JM. p53 and DNA damageinducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A 2002;99:12985-90
14. Ford JM. Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res 2005; 577:195-202.
15. Smith ML, Chen IT, Zhan Q, O'Connor PM, and Fornace AJ Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 1995;10:1053-9.
16. Smith ML, Fornace AJ Jr. p53-mediated protective responses to UV irradiation. Proc Natl Acad Sci U S A 1997;94:12255-7.
17. Smith ML, Ford JM, Hollander MC et al. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol 2000;20:3705-14.
18. Fan S, Smith ML, Rivet DJ et al. Disruption of p53 sensitizes breast cancer MCF7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
19. Gudkov A and Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Human Mol Genet 2007;16:67-72.
20. Hollander MC, Philburn RT, Patterson AD, et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis.Proc Natl Acad Sci U S A 2005;102:13200-5.
21. Hu JJ, Hall MC, Grossman L, et al. Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 2004; 64:1197-1201
22. Brooks PJ, Wise DS, Berry DA et al. The oxidative DNA lesion 8,5'-(S)-cyclo-2′-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cells. J Biol Chem 2000;275:22355-62.
23. Van Rees BP, Cleton-Jansen AM, Cense HA et al. Molecular evidence of field cancerization in a patient with 7 tumors of the aerodigestive tract. Hum Pathol 2000;31:269-71.
24. Kammori M, Poon SS, Nakamura et al. Squamous cell carcinomas of the esophagus arise from a telomereshortened epithelial field. Int J Mol Med 2007; 20:793-9.
25. McDonald SA, Greaves LC, Gutierrez-Gonzales L et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 2008;134:500-10.